GlassScriptPhysician profile
Robert W Godley
NPI 1710989124
$3,881.95
in general payments reported to CMS, 2019-2025
16 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,136 · 2020: $165 · 2021: $25.42 · 2022: $278 · 2023: $375 · 2024: $390 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223 · Travel and Lodging: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.75 |
| Travel and Lodging | $1,054.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,795.71 | 2019-2025 | Evoque, Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $955.76 | 2019-2024 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $273.43 | 2019-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $141.71 | 2023-2024 | Assure Wcd |
| Amgen INC. | $136.21 | 2022-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $129.78 | 2022-2024 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $90.92 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $67.24 | 2022-2023 | Verquvo |
| Biotronik INC. | $56.32 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $53.87 | 2022-2024 | Brilinta |
| Pfizer INC. | $46.88 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.69 | 2023-2025 | Lifevest |
| Cardiovascular Systems INC. | $35.82 | 2023 | Diamondback Coronary |
| Heartflow, INC. | $33.99 | 2025 | |
| Amarin Pharma, INC. | $15.60 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Godley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.